8-K filing — AIM ImmunoTech Inc. (AIM)
Filed: 2026-09-14 AccNo: 0001493152-26-042592 Size: 253 KB Item 1.01: Entry into a Material Definitive Agreement Item 3.02: Unregistered Sales of Equity Securities Item 9.01: Financial Statements and Exhibits
Stocks · News reference
AIM ImmunoTech Q2 EPS $(0.43) Misses $(0.18) Estimate, Sales $26.000K Up From $25.000K YoY
AIM ImmunoTech (AMEX:AIM) reported quarterly losses of $(0.43) per share which missed the analyst consensus estimate of $(0.18) by 138.89 percent. This is a 88.32 percent increase over losses of $(3.68) per share from
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
AIM ImmunoTech Significantly Expands Ampligen® Global Patent Estate with Long COVID Protection Across Europe and the United Kingdom Through 2041
AIM ImmunoTech announced patent protection for Ampligen across 18 European countries and the United Kingdom through June 2041 for Long COVID treatment. The company also recently secured a U.S. patent for Ampligen combined with pembrolizumab for cancer treatment. These patents strengthen AIM's global intellectual property position around its dsRNA immunomodulator platform across multiple therapeutic indications.
AIM ImmunoTech shares are trading lower. The company announced USPTO has granted a patent covering the use of drug Ampligen in combination with the PD-1 checkpoint inhibitor pembrolizumab for the treatment of cancer.
AIM ImmunoTech Announces USPTO Granted Patent Covering Use Of Ampligen In Combination With Pembrolizumab For Cancer Treatment, Expiring December 20, 2039